| 產(chǎn)品名稱 | Remogliflozin - GSK 189074 |
| 產(chǎn)品貨號 | Axon 1634 CAS [329045-45-6] MF C23H34N2O7MW 450.53 Purity: 99% Soluble in water and DMSO Description Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Its prodrug is Remoglifozin etabonate (GSK 189075), investigated as a treatment of anti diabetes type II References Certificates Categories Extra info Y Fujimori et al. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. J. Pharmacol. Exp. Ther.?2008, 327(1), 268-276. Certificate of Analysis Material Safety Data Sheet Diabetes & Metabolism SGLT2 Sodium-Glucose Co-transproter SGLT2 inhibitor Chemical name (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yloxy)tetrahydro-2H-pyran-3,4,5-triol Parent CAS No. [329045-45-6] Order Size Unit Price Stock 5 mg €135.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Remogliflozin - GSK 189074Axon 1634 CAS [329045-45-6] MF C23H34N2O7
Description
Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Its prodrug is Remoglifozin etabonate (GSK 189075), investigated as a treatment of anti diabetes type II
SGLT2 inhibitor
Chemical name(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yloxy)tetrahydro-2H-pyran-3,4,5-triol Parent CAS No.[329045-45-6] |
| 產(chǎn)品資料 |
